La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Invion Résultats passés
Passé contrôle des critères 0/6
Invion's earnings have been declining at an average annual rate of -0.9%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been growing at an average rate of 5% per year.
Informations clés
-0.9%
Taux de croissance des bénéfices
3.2%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 31.2% |
Taux de croissance des recettes | 5.0% |
Rendement des fonds propres | -8.4% |
Marge nette | -34.1% |
Dernière mise à jour des bénéfices | 31 Dec 2023 |
Mises à jour récentes des performances passées
Recent updates
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Invion Limited's (ASX:IVX) CEO For Now
Nov 22We Think Invion (ASX:IVX) Can Afford To Drive Business Growth
Jul 07Here's Why We're Not Too Worried About Invion's (ASX:IVX) Cash Burn Situation
Mar 24Is Invion (ASX:IVX) In A Good Position To Invest In Growth?
Dec 08We're Not Very Worried About Invion's (ASX:IVX) Cash Burn Rate
Aug 16A Look At The Fair Value Of Invion Limited (ASX:IVX)
Nov 04Estimating The Intrinsic Value Of Invion Limited (ASX:IVX)
Mar 23We Think Invion (ASX:IVX) Can Easily Afford To Drive Business Growth
Nov 26Ventilation des recettes et des dépenses
Comment Invion gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
31 Dec 23 | 4 | -1 | 2 | 0 |
30 Sep 23 | 4 | -2 | 2 | 0 |
30 Jun 23 | 4 | -2 | 2 | 0 |
31 Mar 23 | 4 | -2 | 2 | 0 |
31 Dec 22 | 4 | -2 | 2 | 0 |
30 Sep 22 | 4 | -2 | 3 | 0 |
30 Jun 22 | 3 | -2 | 3 | 0 |
31 Mar 22 | 3 | -2 | 3 | 0 |
31 Dec 21 | 2 | -2 | 2 | 0 |
30 Sep 21 | 2 | -2 | 2 | 0 |
30 Jun 21 | 2 | -1 | 2 | 0 |
31 Mar 21 | 3 | -1 | 2 | 0 |
31 Dec 20 | 3 | -1 | 2 | 0 |
30 Sep 20 | 3 | -1 | 2 | 0 |
30 Jun 20 | 3 | -1 | 3 | 0 |
31 Dec 19 | 5 | -2 | 4 | 0 |
30 Sep 19 | 4 | -2 | 4 | 0 |
30 Jun 19 | 4 | -3 | 4 | 0 |
31 Dec 18 | 2 | -1 | 2 | 0 |
30 Sep 18 | 1 | -1 | 2 | 0 |
30 Jun 18 | 1 | -1 | 1 | 0 |
31 Mar 18 | 0 | -6 | 1 | 0 |
31 Dec 17 | 0 | -6 | 1 | 0 |
30 Sep 17 | 0 | -4 | 1 | 0 |
30 Jun 17 | 0 | -2 | 1 | 0 |
31 Mar 17 | 0 | 0 | 1 | 0 |
31 Dec 16 | 0 | 2 | 2 | 0 |
30 Sep 16 | 0 | -1 | 3 | 0 |
30 Jun 16 | 0 | -4 | 3 | 0 |
31 Mar 16 | 0 | -8 | 4 | 0 |
31 Dec 15 | 0 | -11 | 4 | 0 |
30 Sep 15 | 0 | -12 | 4 | 0 |
30 Jun 15 | 0 | -13 | 5 | 0 |
31 Mar 15 | 0 | -11 | 5 | 0 |
31 Dec 14 | 0 | -9 | 5 | 0 |
30 Sep 14 | 0 | -8 | 4 | 0 |
30 Jun 14 | 0 | -7 | 4 | 0 |
31 Mar 14 | 0 | -6 | 4 | 0 |
31 Dec 13 | 0 | -5 | 3 | 0 |
30 Sep 13 | 0 | -5 | 3 | 0 |
Des revenus de qualité: IVX is currently unprofitable.
Augmentation de la marge bénéficiaire: IVX is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: IVX is unprofitable, and losses have increased over the past 5 years at a rate of 0.9% per year.
Accélération de la croissance: Unable to compare IVX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: IVX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).
Rendement des fonds propres
ROE élevé: IVX has a negative Return on Equity (-8.39%), as it is currently unprofitable.